Article Text

Download PDFPDF
The RCPCH care pathway for children with drug allergies: an evidence and consensus based national approach
  1. George du Toit1,
  2. Kate Lloyd2,
  3. Louise Sinnott3,
  4. Debra Forster4,
  5. Moira Austin5,
  6. Christine Clark6,
  7. David Tuthill7,
  8. Jane S Lucas8,
  9. Nicola Brathwaite9,
  10. John Warner10 on behalf of the Science and Research Department, Royal College of Paediatrics and Child Health
  1. 1Paediatric Allergy, Guy's and St Thomas' NHS Foundation Trust, London, UK
  2. 2Science and Research Department, Royal College of Paediatrics and Child Health, London, UK
  3. 3North West Specialised Commissioning Team, Warrington, UK
  4. 4Children's Clinic (South), RCN Nurses Allergy Group, Nottingham Children's Hospital, London, UK
  5. 5Anaphylaxis Campaign, Farnborough, UK
  6. 6Pharmacist, London, UK
  7. 7Department of Paediatrics, Children's Hospital for Wales, Cardiff, UK
  8. 8Division of Infection, Inflammation and Immunity, NIHR Respiratory Biomedical Research Unit, Sir Henry Wellcome Laboratories, University of Southampton, Southampton, UK
  9. 9Paediatric Allergy, King's College Hospital NHS Foundation Trust, London, UK
  10. 10Department of Paediatrics, Imperial College, St Mary's Hospital Campus, London, UK
  1. Correspondence to Dr George du Toit, Paediatric Allergy, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK; georgedutoit{at}


Aims The Royal College of Paediatrics and Child Health (RCPCH) was commissioned by the Department of Health to develop a drug allergy pathway. It focuses on defining the competences to improve the equity of care received by children.

Method The drug pathway was developed by a multidisciplinary working group and was based on a comprehensive review of evidence. The team decided to focus on IgE-mediated reactions as these have the greatest potential to be life-threatening.

Results The results are presented in four parts: evidence review, pathway mapping, external review and core knowledge documents. The evidence review found a high percentage of putative penicillin allergy is not confirmed by objective testing and that resensitisation to β-lactam drugs was infrequent. It also highlighted the importance of a detailed history and accurate diagnosis along with clear communication of test results to both family and primary care.

Conclusions This pathway demonstrates the spectrum of drug allergy is varied and may differ for young children compared with older children and adults. The authors highlight the paucity of evidence to support allergy testing for most drugs, in children, other than supervised incremental provocation tests (when indicated). Acute presentations require emergency health professionals to address underlying allergic issues, including recognition and avoidance of potential drug allergy triggers. Non-acute presentations may include multi-system symptoms which may have a broad differential diagnosis; this document signposts to the relevant partners in the RCPCH care pathway portfolio. Management combines a care package including a definitive diagnosis, initiating treatments and ongoing education.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This project was funded by the Department of Health.

  • Competing interests GdT: Allergy Therapeutics, ALK, Phadia, Danone, Nutrition SHS; DT: Nutricia, SMA; CC: Stiefel, Galderma, Almirall, Leo, JL: ALK; JW: Novartis, Danone, Airsonette, Merck, Allergy Therapeutics, Phadia Research, GSK, AstraZeneca, Merck, Allergy Therapeutics, ALK.

  • Provenance and peer review Not commissioned; internally peer reviewed.